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Running title - Stromal morphometry in stage II colorectal cancer 
 
Abstract 
Introduction: The biological importance of tumour-associated stroma is increasingly apparent, yet 
clinical utility remains ill-defined. In stage-II / Dukes B colorectal cancer (CRC), clinical biomarkers are 
urgently required to direct therapeutic options. We report here prognostic/predictive analyses, and 
molecular associations, of stromal morphometric quantification in the Quick and Simple and Reliable 
(QUASAR) trial of CRC. Materials and methods: Relative proportions of tumour epithelium (PoT) or 
stroma (PoS) were morphometrically quantified using digitised haematoxylin and eosin sections 
derived from 1,800 patients enrolled in QUASAR which randomised 3,239 (91% stage II) CRC patients 
between adjuvant fluorouracil/folinic acid (FUFA) chemotherapy and observation. The 
prognostic/predictive value of PoT/PoS measures were determined by stratified log-rank analyses. 
Results: High tumour stroma (≥50%) was associated with increased recurrence risk: 31.3% (143/457) 
recurrence for ≥50% versus 21.9% (294/1,343) if <50% [Rate ratio (RR)=1.62; 95%CI 1.30-2.02, 
p<0.0001)]. For stromal proportions of ≥65%, 40% (46/115) of patients had recurrent disease within 
10 years. The adverse prognostic effect of high stroma was independent of established prognostic 
variables, and maintained in stage II / Dukes B patients (RR=1.62; 95%CI=1.26-2.08; p=0.0002). KRAS 
mutation in the presence of high stroma augmented recurrence risk (RR=2.93; 95%CI=1.87-4.59; 
p=0.0005). Stromal morphometry did not predict response to FUFA chemotherapy. Discussion: 
Simple digital morphometry applied to a single representative H&E section identifies CRC patients 
with over 50% higher risk of disease recurrence. This technique can reliably partition patients into 
sub-populations with differential risks of tumour recurrence in a simple and cost-effective manner. 
Further prospective validation is warranted. 
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INTRODUCTION 
The use of adjuvant chemotherapy in colorectal cancer (CRC) following presumptive curative 
resection is directed by high-quality pathological assessment.1-3 Detection of tumour within lymph 
nodes (stage III disease) is generally regarded as an absolute indication for adjuvant therapy1,4,5 
because of significant clinical benefit (~10% absolute improvement in overall survival [OS].6,7 The 
value of adjuvant chemotherapy in locally advanced, node-negative (stage II) disease is less clear 
because the more modest benefits (~4% improvement in OS),8 may not outweigh the toxicity and 
patient inconvenience.1,9,10  
 
Thus, adjuvant chemotherapy is generally restricted to a minority of stage II patients with ‘high-risk’ 
pathological features including extra-mural vascular and/or peritoneal invasion.1,11,12 Such features 
impart a recurrence risk of similar magnitude to that associated with lymph node metastasis2 and so 
serve to identify stage II patients who may derive worthwhile benefit from adjuvant regimens.1,4,5 A 
limitation of this approach is that identification of such features is subjective with variability in 
reporting quality and reproducibility.3,13 Also, only a minority of recurrences among these ‘high-risk’ 
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patients will be prevented by ‘appropriate’ chemotherapy,8,10,14 and it is not currently possible to 
identify who is more or less likely to benefit.15 Consequently, identification and clinical validation of 
effective prognostic and, in particular, predictive biological indicators would help facilitate 
therapeutic decisions.  
 
Mismatch repair (MMR) / microsatellite instability (MSI) testing can identify CRC patients at a 
reduced risk of recurrence for whom adjuvant therapy is usually not indicated.14,16-18 However, only a 
minority of CRC patients, 12-15% at most, demonstrate MSI and/or attenuated expression of one or 
more MMR proteins.16,17 The Oncotype DX® recurrence score has been prospectively validated for 
assessment of recurrence risk in post-operative stage II colon cancer patients but is of only modest 
prognostic value and is not predictive of chemotherapy benefit.19 Widely applicable biomarkers are 
thus required, particularly ones that negate the need for expensive molecular testing,20-23 for cost-
effective application in a diverse, non-specialist setting. 
 
Associations between disease recurrence and cancer-associated stromal gene23-27 or protein28-35 
expression has been reported in a variety of malignant conditions with some evidence of differential 
chemotherapeutic response defined by stromal gene expression profiles.36-38  In CRC, the potential 
prognostic value of stromal gene expressional analysis is highlighted by inclusion in the Oncotype 
DX® colon recurrence score.23 Whilst the majority of studies have been performed at the 
transcriptomic or proteomic level, several studies indicate that,  using established mathematical 
principles,39-42 simple, inexpensive, visual evaluation of tumour composition43-47 or stromal 
phenotype48,49 may yield equally valuable prognostic information.  
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Studies by Mesker et al,50,51, West et al,52 and Huijbers et al,47 suggest that simple visual47,50,51 or 
morphometric52 assessment of CRCs provides independent prognostic information, a premise 
recently tested in the VICTOR CRC trial.47 To improve on the reproducibility of these visual 
estimation methods described by Huijbers et al (2013),47 we have developed a quantitative 
compositional analysis technique utilising digital pathology.53 This methodology, however, has so far 
only been tested in a small cohort of 145 all-stage CRC patients.52 
 
Given biological plausibility, existing literature, and the recent recognition of CRCs with 
mesenchymal/stroma rich gene signatures as biologically distinct and clinically significant tumour 
sub-populations54, we hypothesise that quantitative tumour-stromal compositional analysis might 
represent a simple yet powerful methodology to determine risk of disease recurrence and 
differential response to adjuvant chemotherapy in CRC. We report here results of a test of this 
hypothesis utilising digitised material and clinicopathological data from the QUASAR trial, which 
randomised 3,239 predominantly stage II (91%) CRC patients between 6 months of fluorouracil and 
folinic acid (FUFA) chemotherapy and observation.8  
 
MATERIALS AND METHODS  
Ethics 
Ethical approval was obtained from both the West Midlands Multi-Centre Research Ethics 
Committee (JR/MT/MREC/02/7/56a) and the Northern and Yorkshire Research Ethics Committee 
(08/H0903/62).  
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Patients 
The design and details of QUASAR (ISRCTN82375386) are reported elsewhere.8 Briefly, 3,239 
patients (post-curative resection for colon or rectal cancer, 91% stage II disease) were randomized to 
FUFA chemotherapy (n=1622) or observation only (n=1617) with chemotherapy considered in the 
event of recurrence.  
 
Study design 
Datasets were randomly partitioned into exploratory and validatory groups (figure 1). For initial 
analyses, an exploratory dataset (n=399), representative of the entire study cohort, was used to 
develop a priori prognostic50-52 and predictive hypotheses using data derived from 3 specific 
analytical tumour regions (figure 2). Independent validation was performed using a separate 
validatory patient cohort dataset (n=1,800). All pathological and laboratory assessments were 
undertaken blind to the patients’ treatment allocation and clinical outcomes. 
Clinicopathological data 
Pathological data (TNM 5) were abstracted by central review of anonymised histopathological 
reports collected from local units.  
 
Morphometric analysis of tumour components 
One tumour block per patient was selected for analyses. When more than one block was available, 
blocks were chosen to optimally represent the area of maximal tumour infiltration of the bowel wall. 
Histological sections (5μm thick) were cut from selected tumour blocks and stained with 
haematoxylin and eosin (H&E) using standard methodologies.  
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H&E sections were digitised at x20 magnification (0.46 μm per pixel) using an automated scanning 
system (Aperio XT, Aperio Technologies, Vista, CA, USA). Slide viewing for quality control (QC) and all 
subsequent quantification processes were performed using open source slide viewing software 
(Aperio ImageScope v10.2.2.2352, Aperio Technologies, Vista, CA, USA). Following image QC, and 
methodological and statistical validation using existing datasets, a systematic random sample of 50 
points was superimposed on selected areas (figure 2) using web-based virtual graticule software 
(RandomSpot, University of Leeds, Leeds, UK).  
 
For exploratory analyses (figure 1), three areas from each selected H&E section were identified for 
random point grid application (figure 2). The luminal tumour area (LT) was defined as a 9mm2 area of 
greatest tumour epithelial cell density at the luminal surface of the tumour (figure 2A). The highest 
tumour density (HT) area was defined as a 9mm2 area of highest tumour cell density (if not located 
at the luminal surface); figure 2B. The whole tumour (WT) area included the total area of tumour 
infiltration extending from the luminal surface and encompassing the lateral and deep invasive 
fronts of tumour (figure 2C). For 9mm2 regions, large areas of necrosis and mucin were avoided if 
possible. 
 
Tumour morphometry was determined by counting the frequency of occurrence of specific 
phenotypic categories underlying each of the 50 points. The following categories were used; 1: 
tumour epithelium, 2: tumour-associated stroma, 3: necrosis, 4: vessel, 5: inflammation, 6: tumour 
lumen, 7: mucin, 8: muscle and 0: non-informative / unclassifiable. Tumour morphometry was 
performed by technical staff under direct supervision of experienced pathologists (GH / PQ).  
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For final outcome analyses, relative tumour composition was expressed as a percentage of total 
informative points for tumour epithelium (PoT – phenotype category 1 only) or stroma (PoS – 
phenotype category 2 only) or other categories (phenotype categories 3-8). 
 
Determination of morphometric stratification cut-off points 
For prognostic / predictive analyses, we applied the ‘pool adjacent violators’ algorithm to the 
continuous variables PoT or PoS to determine points where the relationship between the measured 
variable (e.g. stroma) and the recurrence risk demonstrated a distinct change55-59. Analyses were 
performed (by KH/RG) across all tumour / stromal measurements derived from each area within the 
training set (n=399) indicating the most appropriate cut-off values to stratify scores into two (<50%, 
≥50%) or four groups (<35%, 35-49%, 50-64%, ≥65%).  
 
Statistics and bioinformatics 
The prognostic/predictive value of PoT/PoS measures were determined by stratified log-rank 
analyses.60 For analyses of the prognostic value of PoT or PoS, recurrence was used as outcome 
measure. Recurrence is a reliable marker of the natural history of the cancer and correlates well with 
the effects of adjuvant chemotherapy on survival.61 Recurrence was calculated as the time elapsed 
from randomisation to recurrence with censoring at last contact with patient or death without 
recurrence. For assessment of the prognostic value of variables, recurrence rates over the whole 
follow-up period were analysed. Because adjuvant FU/FA reduces the risk of recurrence only in the 
first two years following randomisation with no further benefit, or loss of benefit, thereafter,8 
investigations of differential treatment efficacy within subgroups included recurrences over the first 
two years only. Analyses were generally performed using SAS version 9.2 (SAS Institute Inc., Cary, 
NC) by biostatisticians within the Birmingham Clinical Trials Unit, University of Birmingham, UK (KH) 
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and The Nuffield Department of Population Health, University of Oxford, Oxford, UK (RG). 
Integrity of scoring data was validated by inter-observer comparison analysis of scores generated by 
2 independent observers using kappa statistics on 2,975 individual data points. Inter-observer 
variability analyses were discontinued after 10 cases because of extremely high inter-observer 
agreement (see below).  Subsequent to inter-observer analyses, all generated data were visually 
screened by experienced pathologists (GH/PQ).  
 
RESULTS  
Tumour tissue was obtained for 75% (2,439/3,239) of QUASAR participants with material 
from 2,199 patients suitable for analysis (figure 1). Comparisons of morphometry scores 
generated by two independent observers on 2,975 informative data points confirmed high 
agreement of 99.1%, Cohen’s kappa=0.986 (95%CI=0.985-0.990; p<0.001). 
Exploratory dataset analyses 
Analyses of the 399-patient exploratory dataset provided no indication of any 
significant association between tumour or stroma density and chemotherapeutic 
efficacy (Supporting information, figure S1); prognostic analyses of the exploratory 
dataset therefore included both treated and control patients. A higher percentage of 
stroma cells was associated with worse prognosis in the exploratory data set, 
particularly in the ‘highest’ and ‘whole’ stroma categorisations (Supporting 
information, figures S2-S7). A lower percentage of tumour cells was also associated 
with worse prognosis in the exploratory data set, particularly in the ‘highest’ and 
‘lumenal’ tumour categorisation. 
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Validatory dataset analyses 
Analyses of the 1800-patient validatory dataset also provided little evidence for any association 
between tumour or stroma density and chemotherapy efficacy (see below). Therefore, prognostic 
analyses of the validatory data again included both chemotherapy treated and control patients. 
 
There was a highly significant trend of increasing 10-year recurrence risk with increasing stromal 
proportions in the whole tumour area in the test data set (log-rank p<0.0001; figure 3). By contrast, 
other stromal and tumour scores were only weakly associated with worse prognosis (Supporting 
information, figures S8-S12). This highly significant association in the whole stroma categorisation is 
consistent with the exploratory data analyses where the association was strongest in the whole and 
highest stroma categories, whereas the lack of association in the highest stroma category is not. 
  
For stromal proportions of ≥65% in the whole tumour region, the 10-year risk of recurrent disease 
was 43% compared to 25% for tumours with <50% scores. The adverse prognostic impact of higher 
whole tumour PoS scores remained highly significant (p=0.0002) in analyses restricted to stage II / 
Dukes B patients only (figure 4). Notably, there was no association between the pattern of 
recurrence (local versus distant) and increasing stromal proportions within the whole tumour region 
(p=0.105). 
 
The distribution of PoS risk categories derived from the WT region differed significantly by tumour 
site, stage, histological subtype and MMR phenotype (table 1). There were significantly more 
tumours classified as PoS ≥65% in the rectum than colon: 11.4% (43/377) compared to 5.1% 
(72/1,423), p<0.0001. There were more low (<35%) PoS scores in Dukes’ B than Dukes’ C lesions 
41.1% (658/1,603) versus 26.7% (43/161), p=0.002. Predictably, there was a lower frequency of PoS 
≥65% lesions in mucinous tumours when compared to adenocarcinomas 1.9% (3/162) versus 6.4% 
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(95/1,473) respectively, p<0.0001). The weak (p=0.012) association of lower scores in the dMMR 
phenotype is also unsurprising given the previously reported interactions between dMMR, 
anatomical location and mucinous and medullary histology. 
  
To investigate whether confounding with other pathological prognostic variables might at least 
partly explain the association of high stroma counts with recurrence, we undertook analyses 
stratified by these other variables using a binary dichotomisation (<50% low, ≥50% high) of PoS 
scores.  The risk of recurrence was over 50% higher in the 25% (457/1,800) of patients with high 
(≥50%) PoS scores than in patients with low (<50%) PoS scores: [Rate ratio (RR)=1.61; 95%CI 1.30-
2.00, p<0.0001)]; figure 5. Analyses stratified by chemotherapy allocation, tumour site and stage did 
not indicate any significant variability in the prognostic importance of stroma. Nor did any other of 
the variables tested except for the analyses stratified by KRAS mutation status where significant 
(p=0.001) heterogeneity was seen with a stronger prognostic association seen in KRAS mutant 
tumours (RR=2.93; 95%CI=1.85-2.55) than in KRAS wild-type tumours (RR=1.14; 95%CI=0.60-1.62), 
(figure 5).  
 
We investigated any differential chemotherapeutic response by PoS measurements using 2 year 
disease recurrence as outcome (figure 6). There were one third fewer recurrences with 
chemotherapy than control within the 2 year post-randomisation period [unstratified analyses; 
RR=0.64; 95%CI=0.49-0.84; p=0.001]. Analyses sub-stratified by increasing WT PoS measures, failed 
to demonstrate a significant interaction between chemotherapy benefit and PoS measurements 
(ptrend=0.22; figure 6). 
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Unexpectedly, the beneficial effect of chemotherapy was as strong in analyses of all recurrences as 
in analyses of 2-year recurrence (Supporting information, figures S13-S16): 20.8% (183/880) of 
adjuvant treated patients recurred at 10 years compared to 27.6% (254/920) of untreated patients 
[RR=0.71; 95%CI=0.59-0.85; p=0.0003]. There was a suggestion (ptrend=0.039) that the reduction in 
10-year recurrence with chemotherapy increased with increasing stromal proportions (PoS) in the 
WT region (Supporting information, figures S13-S16).  
 
Analysis of other prognostic variables were performed to compare the prognostic strength of these 
variables with that of stroma count, and to determine if their prognostic value was independent of 
stromal count. (Supporting information, figures S17-S23) A borderline significant interaction 
between stroma and Dukes stage (ptrend=0.032) was seen with no apparent prognostic effect of nodal 
status in tumours with ≥65% PoS values. No interactions between TNM T-category (TNM 5) and 
increasing PoS values were identified with the favourable prognostic effect of T3 versus T4 disease 
appearing similar across PoS subgroups (Supporting information, figure S18). Small subgroup 
numbers (2 recurrences in 5 patients with dMMR tumours with ≥65% PoS measurements) precluded 
any meaningful investigation of potential interactions (Supporting information, figure S20). KRAS 
mutation was associated with a higher disease recurrence rate when compared to KRAS wild-type 
tumours [115/401; 28.7% versus 170/780; 21.8% recurred (RR=1.39; 95%CI=1.09-1.78, p=0.009); 
(Supporting information, figure S21) with the adverse prognostic effect of tumour PoS appearing 
greater in KRAS-mutant than KRAS wild-type tumours (Supporting information, figure S21). These 
observations parallel the analysis of dichotomised stroma stratified by KRAS mutation status (figure 
5). BRAF status was non-prognostic (Supporting information, figure S22). 
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DISCUSSION 
By applying simple digital morphometry  to tumour blocks from 2,199 QUASAR CRC trial patients,8 
we have demonstrated the powerful prognostic value of tumour-stromal counts; our division of 
tumours into four prognostic groups based on cut-offs in the validatory cohort was confirmed in the 
test data with high intra-tumoural stroma (>65%) being associated with a disease recurrence risk 
approximately twice that of patients whose tumours contained low intra-tumoural stroma (<50%).  
 
Our primary analysis with 2-year disease recurrence as outcome failed to substantiate any predictive 
chemotherapeutic effect of stroma count (figure 6). However, benefits of chemotherapy appeared 
to increase with increasing stroma count and this trend reached statistical significance in analyses of 
all recurrence stratified by intra-tumoural stromal proportion, suggesting that the benefits of 
chemotherapy are at  least as good in the higher risk stroma groups. This contrasts with previous 
reports suggesting that tumour associated stroma may attenuate the efficacy of chemotherapeutic 
agents.62-70 Although some propose pharmacological targeting of tumour associated stroma as a 
mechanism of countering chemoresistance (and thus enhancing chemotherapeutic efficacy) in 
cancer 70-73 the present study provides no support for this approach, at least in CRC. 
 
The mechanism by which varying proportions of intra-tumoural stroma influence clinical outcome 
(also reported in breast,43,46 lung,44,74 ovarian,75 cutaneous,45 and prostatic76 neoplasia) is unknown. 
Postulated theories commonly relate to stroma-associated cellular phenotypes and include 
enhanced pro-invasive signalling by intra-stromal myofibroblasts77 or growth factor/cytokine 
production by cancer associated fibroblasts (CAF) inducing angiogenesis, increased tumour growth 
and invasion.71,78-81 Other possible explanations may involve mechanisms relating to tumour 
hypoxia82 and/or tumour associated inflammation.71,83 The possibility that differential proportions of 
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tumour and stroma may simply indirectly reflect the stage of disease has been previously 
suggested.51,52 We found no evidence for this potential explanation of the prognostic effect of 
stroma with similar findings in stratified and unstratified analyses and no interaction between 
stromal proportions, Dukes or TNM T categories.  
 
Stromal TGFβ,84,85 a critical regulator of epithelial-mesenchymal transition,86 is required to support 
metastatic dissemination when mutational inactivation of TGFβ has occurred, as is common in CRC.87 
In view of the possible role of stromal-derived TGFβ in the promotion of metastases in CRC,87 the 
observation that KRAS mutant, high stromal tumours had a significantly more elevated recurrence 
risk than KRAS wild-type high stromal lesions is noteworthy. There is abundant evidence indicating 
that RAS signalling operates in unison with TGFβ to enhance tumour cell invasiveness, either 
directly88,89 or by suppressing TGFβ mediated growth inhibitory signals.90,91 A note of caution, 
however, is that the association between stroma and KRAS mutation was unanticipated, so our 
findings need confirming, but should encourage further investigation. 
 
In summary, our analyses of the largest reported validation dataset  confirm the prognostic value of 
simple morphometric analyses and reciprocate similar findings of morphological / morphometric 
prognostic studies in CRC reported by Mesker et al50,51, Huijbers et al92 and West et al.52 Collectively, 
our data and that of others50-52,92 adds substance to the concept that simple morphometric appraisal 
of the quantitative relationship of tumour and / or tumour stroma can reliably identify patient sub-
populations with differential risks of tumour recurrence in a simple and cost-effective manner. Our 
group (led by AW/DT) are now in the process of using the described dataset to develop an 
automated computational analytical platform for CRC prognostication. 
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Figure legends  
Figure 1 - Study schema.  
Figure 2 - Tumour regions for morphometric analysis. (A) Selected tumor block representing maximal 
lateral and deep tumor infiltration; (B) “Luminal” 9mm2 area; (C) “Highest” 9mm2 area of maximal 
tumor epithelial density (if away from luminal surface; (D) “Whole” tumor area encompassing lateral 
and deep invasive fronts. Scale bars=5mm  
Figure 3 - Recurrence risk stratified by proportion of stroma (PoS) in the whole tumour (WT) region – 
validatory dataset, stage II / III patients (n=1,800). 
Figure 4 - Recurrence risk stratified by proportion of stroma (PoS) in the whole tumour (WT) region – 
validatory dataset, stage II patients only (n=1,603) 
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Figure 5 - Recurrence risk by dichotomised proportion of stroma (PoS) stratified by 
clinicopathological variables in the whole tumour (WT) region. Validatory dataset (n=1,800); (O-
E)=observed minus expected; Var=variance 
 
Figure 6 - Recurrence risk by chemotherapy (2 years) sub-stratified by tumour morphometric 
subgroups. Validatory dataset (n=1,800); (O-E)=observed minus expected; Var=variance. 
 
List of online supporting information 
 
Figure S1 - Recurrence risk (2 years) by chemotherapy, stratified by sub-stratified by tumour 
morphometric subgroups 
 
Figure S2 - Recurrence risk by proportion of stroma (PoS) in highest tumour (HT) area 
 
Figure S3 - Recurrence risk by proportion of stroma (PoS) in the luminal tumour (LT) area 
 
Figure S4 - Recurrence risk by proportion of stroma (PoS) in whole tumour (WT) area 
 
Figure S5 – Recurrence risk by proportion of tumour (PoT) in the highest tumour (HT) area 
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Figure S6 – Recurrence risk by proportion of tumour (PoT) in the luminal tumour (LT) area 
 
Figure S7 - Recurrence risk by proportion of tumour (PoT) in whole tumour (WT) area 
 
Figure S8 - Recurrence risk by proportion of stroma (PoS) in highest tumour (HT) area 
 
Figure S9 - Recurrence risk by proportion of stroma (PoS) in luminal tumour (LT) area 
 
Figure S10 - Recurrence by proportion of tumour (PoT) in highest tumour (HT) area 
 
Figure S11 - Recurrence by proportion of tumour (PoT) in luminal tumour (LT) area 
 
Figure S12 - Recurrence by proportion of tumour (PoT) in whole tumour (WT) area 
  
Figure S13 - Recurrence risk by chemotherapy stratified by proportion of stroma (PoS) in the whole 
tumour (WT) region across clinicopathological sub-groups 
 
Figure S14 - Recurrence risk by chemotherapy stratified by proportion of stroma (PoS) in the whole 
tumour (WT) region across clinicopathological sub-groups 
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Figure S15 - Recurrence risk by chemotherapy stratified by proportion of stroma (PoS) in the whole 
tumour (WT) region across clinicopathological sub-groups 
 
Figure S16 - Recurrence risk by chemotherapy stratified by proportion of stroma (PoS) in the whole 
tumour (WT) region across molecular sub-groups 
 
Figure S17 – Recurrence risk by AJCC stage stratified by proportion of stroma (PoS) in the whole 
tumour (WT) region 
 
Figure S18 – Recurrence risk by T-stage (TNM 5) stratified by proportion of stroma (PoS) in the whole 
tumour (WT) region 
 
Figure S19 – Recurrence risk by lymph node yield stratified by proportion of stroma (PoS) in the 
whole tumour (WT) region 
 
Figure S20 – Recurrence risk by extra-mural vascular invasion stratified by proportion of stroma 
(PoS) in the whole tumour (WT) region 
 
Figure S21 – Recurrence risk by mismatch repair status stratified by proportion of stroma (PoS) in the 
whole tumour (WT) region 
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Figure S22 – Recurrence risk by KRAS mutation status stratified by whole tumour PoS 
 
Figure S23 – Recurrence risk by BRAF mutation status stratified by whole tumour PoS 
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Table 1 – Patient characteristics by proportion of stroma (whole tumour area)  
 
% PoS categories 
<35%  
n, (%) 
35%-49%  
n, (%)] 
50%<65%  
[n, (%)] 
≥65%  
[n, (%)] 
p-value 
All patients 
(n=1,800) 
716 
(39.78) 
627 
(34.83) 
342 
(19.0) 
115 
(6.39) 
n/a 
Colon 
(n=1,423) 
597 
(41.95) 
497 
(34.93) 
257 
(18.06) 
72 
(5.06) 
<0.0001 
Rectum 
(n=377) 
119 
(31.56) 
130 
(34.48) 
85 
(22.55) 
43 
(11.41) 
Dukes B / Stage II 
(n=1,603) 
658 
(41.05) 
553 
(34.50) 
295 
(18.40) 
97 
(6.05) 
0.0019 
Dukes C/Stage III 
(n=161) 
43 
(26.71) 
62 
(38.51) 
40  
(24.84) 
16  
(9.94) 
T3 
(n=1,362) 
545 
(40.01) 
481 
(35.32) 
259 
(19.02) 
77 
(5.65) 
0.865 
T4 
(n=217) 
82 
(37.79) 
76 
(35.02) 
45 
(20.74) 
14 
(6.45) 
EMVI 
(n=161) 
51 
(31.68) 
58 
(36.02) 
41 
(25.47) 
11 
(6.83) 
0.078 
No EMVI 
(n=1468) 
594  
(40.76) 
517  
(35.22) 
271  
(18.46) 
86 
(5.86) 
Well diff. 
(n=151) 
70 
(46.36) 
51 
(33.77) 
26 
(17.22) 
4 
(2.65) 
0.159 
Moderately diff. 
(n=1,343) 
521 
(38.79) 
485 
(36.11) 
256 
(19.06) 
81 
(6.03) 
Poor diff. 
(n=139) 
57 
(41.01) 
40 
(28.78) 
30 
(21.58) 
12 
(8.63) 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mucinous 
(n=162) 
100 
(61.73) 
47 
(29.01) 
12 
(7.41) 
3 
(1.85) 
<0.0001 
AdenoCa, NOS 
(n=1,473) 
548 
(37.20) 
530 
(35.98) 
300 
(20.37) 
95 
(6.45) 
<12 lymph nodes 
(n=999) 
398 
(39.84) 
346 
(34.63) 
193 
(19.32) 
62 
(6.21) 
0.699 
12+ lymph nodes 
(n=544) 
217 
(39.89) 
199  
(36.58) 
101 
(18.57) 
27 
(4.96) 
Female 
(n=705) 
289 
(40.99) 
248 
(35.18) 
130 
(18.44) 
38 
(5.39) 
0.481 
Male 
(n=1,113) 
427 
(39.0) 
379 
(34.61) 
212 
(19.36) 
77 
(7.03) 
Chemotherapy 
(n=880) 
353 
(40.11) 
290 
(32.95) 
178 
(20.23) 
59 
(6.70) 
0.330 
Observation 
(n=920) 
363 
(39.46) 
337 
(36.63) 
164 
(17.83) 
56 
(6.09) 
MMR deficient 
(n=162) 
85 
(52.47) 
48 
(29.63) 
24 
(14.81) 
5 
(3.09) 
0.012 
MMR proficient 
(n=1,290) 
508 
(39.38) 
468 
(36.28) 
241 
(18.68) 
73 
(5.66) 
BRAF-mutant 
(n=92) 
41 
(44.57) 
29 
(31.52) 
17 
(18.48) 
5 
(5.42) 
0.821 
BRAF wild-type 
(n=1,091) 
434 
(39.78) 
389 
(35.66) 
205 
(18.79) 
63 
(5.77) 
KRAS mutant 
(n=401) 
167 
(41.65) 
134 
(33.42) 
76 
(18.95) 
24 
(5.99) 
0.816 
KRAS wild-type 
(n=780) 
307 
(39.36) 
282 
(36.15) 
146 
(18.72) 
45 
(5.77) 
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